West Pharmaceutical Services, Inc. — Q2 2023 Form 10-Q Summary
Business Context and Reporting Period
West manufactures pharmaceutical packaging, containment and drug-delivery systems, analytical services, and contract-manufactured devices. Operations are organized into Proprietary Products and Contract-Manufactured Products. The filing covers the three and six months ended June 30, 2023, compared with the same periods in 2022.
Key Financial Metrics
| Metric | Q2 2023 | Q2 2022 | Six Months 2023 | Six Months 2022 |
|---|---|---|---|---|
| Net sales | $753.8 million | $771.3 million | $1,470.4 million | $1,491.3 million |
| Gross profit | $291.4 million | $321.5 million | $562.7 million | $606.1 million |
| Gross margin | 38.7% | 41.7% | 38.3% | 40.6% |
| Operating profit | $182.5 million | $228.4 million | $337.8 million | $418.1 million |
| Operating margin | 24.2% | 29.6% | 23.0% | 28.0% |
| Net income | $155.1 million | $188.5 million | $295.1 million | $362.3 million |
| Diluted EPS | $2.06 | $2.48 | $3.91 | $4.77 |
Q2 net sales declined 2.3%; six-month sales declined 1.4%. Q2 adjusted operating profit was $185.0 million, with a 24.5% adjusted margin; six-month adjusted operating profit was $349.9 million, with a 23.8% adjusted margin.
- Proprietary Products sales decreased 5.5% in Q2 and 4.3% for the six-month period, primarily because COVID-related sales declined by approximately $106 million and $194 million, respectively.
- Contract-Manufactured Products sales increased 15.3% in Q2 and 13.9% year to date, driven mainly by injection-related device components and pricing.
- Research and development expense increased 14.6% in Q2 and 15.9% year to date, reflecting additional work on new product opportunities, including glass systems.
- Q2 SG&A increased 8.5%, and six-month SG&A increased 5.8%, primarily due to higher compensation and IT-related costs.
- Net cash provided by operating activities was $307.3 million for the first six months, compared with $324.3 million in 2022. Capital expenditures were $157.5 million, compared with $131.9 million.
- Cash and cash equivalents were $796.3 million at June 30, 2023, compared with $894.3 million at December 31, 2022. Working capital was $1,362.6 million.
- Total debt was $207.8 million, including $205.6 million of long-term debt. The $500 million revolving credit facility had $497.6 million of available capacity, including letters of credit, and no outstanding borrowings.
Material Changes Versus the Prior Comparable Period
- Profitability weakened substantially as higher-margin COVID-related sales declined, raw-material and compensation costs remained elevated, and additional plant spending was incurred to support demand.
- Gross margin decreased 300 basis points in Q2 and 230 basis points for the six-month period. Operating margin decreased 540 basis points in Q2 and 500 basis points year to date.
- Q2 operating profit declined 20.1%, while six-month operating profit declined 19.2%. Net income declined 17.7% in Q2 and 18.6% year to date.
- Cash use increased because capital expenditures rose and share repurchases accelerated. The company repurchased $233.5 million of shares during the first six months, including $173.4 million in Q2, under a new $1 billion authorization.
- Interest income increased materially because of higher interest rates, partly offsetting higher interest expense.
Guidance, Outlook, Risks and Unusual Items
- The filing does not provide clear quantitative full-year revenue or earnings guidance.
- A restructuring plan approved in December 2022 is expected to generate approximately $22 million to $24 million of annualized savings and require total charges of approximately $25 million to $27 million. The remaining restructuring obligation was $6.7 million at June 30, 2023.
- The company recorded an $11.6 million year-to-date loss on the disposal of a manufacturing facility, including $2.2 million in Q2, plus $3.4 million of asset impairments year to date.
- Management cited continued high raw-material costs, inflation, supply-chain constraints, foreign-currency volatility, and uncertainty related to global economic conditions. The Russia-Ukraine conflict had not materially affected operations through June 30, 2023, but could contribute to further inflation and supply-chain pressure.
- Key operating risks include demand and product mix, declining or volatile COVID-related demand, customer inventory changes, supply-chain interruptions, dependence on critical suppliers and affiliates, regulatory approval and commercialization of customer products, labor availability, commodity prices, foreign exchange, competition, and healthcare legislation.
- The company added a risk factor concerning potential bank failures and restricted access to deposits or lending commitments. Management stated that cash, operating cash flow, and credit availability should be adequate for foreseeable liquidity needs.
- There were no material changes to commitments and contingencies, no off-balance-sheet financing arrangements beyond ordinary-course purchase obligations and letters of credit, and no legal proceedings reported in Part II.
Important Facts for Investors to Verify
- Whether the decline in COVID-related sales has stabilized and whether higher-margin non-COVID products can offset the lost volume.
- The pace and sustainability of Contract-Manufactured Products growth and its ability to recover margin pressure from inflation.
- Progress toward the stated restructuring savings and the remaining $6.7 million obligation.
- Capital-expenditure requirements, manufacturing-capacity expansion, and the effect on free cash flow.
- The sustainability of share repurchases relative to operating cash generation and liquidity.
- Upcoming debt maturities, including the $82.1 million term loan and $53.0 million Series B notes due in 2024.
- Exposure to raw-material costs, foreign exchange, customer concentration or inventory changes, and supplier or affiliate dependencies.
- The impact of unusual items, including the plant-disposal loss, impairments, restructuring adjustments, hedge results, and tax benefits, on reported and adjusted earnings.